1275 York AvenueNew York, NY 10065
Overview of Dr. Oved
Joseph Oved, MD, is a pediatric hematology and oncology specialist based in New York, NY. He graduated from the New York University School of Medicine in 2013 and completed his pediatrics residency at New York Presbyterian Hospital (Cornell Campus) in 2016. Dr. Oved is experienced in transplantation for non-malignant disorders and in particular inborn errors of immunity and bone marrow failure syndromes. A second focus of his work involves reducing toxicities from hematopoietic cell transplantation and specifically trying to develop non-chemotherapeutic agents for conditioning regimens. He has written several innovative multi-center clinical trials in these areas and his research has been featured in reputed journals such as The Lancet and Cell Stem Cell.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Residency, Pediatrics, 2013 - 2016
New York University School of MedicineClass of 2013
Certifications & Licensure
FL State Medical License 2022 - Present
PA State Medical License 2016 - 2026
NJ State Medical License 2021 - 2025
NY State Medical License 2018 - 2025
American Board of Pediatrics Pediatrics- American Board of Pediatrics Pediatric Hematology-Oncology
Publications & Presentations
PubMed
- 1 citationsAllogeneic haematopoietic stem-cell transplantation for children with refractory systemic juvenile idiopathic arthritis and associated lung disease: outcomes from an i...Michael G Matt, Daniel Drozdov, Elisabeth Bendstrup, Mia Glerup, Ellen-Margrethe Hauge
The Lancet. Rheumatology. 2025-04-01 - Successful hematopoietic cell transplantation utilizing myeloablative reduced-toxicity conditioning in Chediak-Higashi syndrome.Alan Bidgoli, Binni Kunvarjee, Andromachi Scaradavou, Richard J O'Reilly, Jaap Jan Boelens
The Journal of Allergy and Clinical Immunology. 2025-02-01 - A semiautomated microfluidic ELISA for the detection of hemophagocytic lymphohistiocytosis biomarkers.Adrianna Zara Herskovits, William T Johnson, Joseph H Oved, Spencer Irwin, Sital Doddi
American Journal of Clinical Pathology. 2025-01-28
Grant Support
- Phase 2a/2b Study Emapalumab: A Window of Opportunity in Pediatric Aplastic AnemiaSLOAN-KETTERING INST CAN RESEARCH2024–2028
- Phase 2 Bridging Pre-transplant Inflammatory Dampening for Primary Immune Regulatory Disorders (BRIDGE Trial)SLOAN-KETTERING INST CAN RESEARCH2023–2027
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
